The US Supreme Court has refused to hear Purdue Pharma's appeal challenging the invalidation of its OxyContin abuse-deterrent patents, a decision that paves the way for generic drugmakers to launch competing products targeting the lucrative extended-release opioid market. The court's move brings a close to years of contentious litigation, marking another legal setback for the bankrupt company long at the center of the nation's opioid crisis.
Purdue developed a reformulated version of OxyContin, introduced in 2010, in an effort to reduce widespread misuse and addiction associated with the original product. The patented formulation aimed to deter abuse by making it difficult to crush or dissolve, but a federal judge in Delaware ruled in 2023 that Purdue’s patents lacked novelty and were invalid, removing an important barrier for Accord Healthcare and other generic manufacturers.
The Federal Circuit Court of Appeals later affirmed the decision, finding that Purdue’s evidence of commercial success and public health benefit was not sufficiently linked to the specific patent claims. Purdue’s request for Supreme Court review argued that the lower courts misapplied patent law, but justices declined to intervene, leaving the lower court rulings in place.
This legal defeat comes as Purdue and its owners, the Sackler family, face thousands of lawsuits relating to their role in the opioid epidemic. A $7.4 billion settlement reached earlier in 2025 with state governments and opioid victims remains subject to ongoing scrutiny and procedural delays. The Supreme Court’s decision effectively legitimizes the production and sale of generic OxyContin, increasing competition in the pain management market while diminishing the company’s dominance.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!